Table 2 Tumor response to doxorubicin in vitro treatment.
Patient | Cell number in control samples | Cell number in treated samples | Cell number variation (%) | Response |
|---|---|---|---|---|
1 | 2307 | 1543 | - 33,12 | R |
2 | 335 | 297 | - 11,34 | NR |
3 | 2611 | 2472 | - 5,32 | NR |
4 | 2800 | 2575 | - 8,04 | NR |
5 | 472 | 216 | - 54,24 | R |
6 | 445 | 278 | - 37,53 | R |
7 | 354 | 304 | - 14,12 | NR |
8 | 1339 | 1412 | + 5,45 | NR |
9 | 1581 | 1337 | - 15,43 | NR |
10 | 1405 | 625 | - 55,52 | R |
11 | 644 | 656 | + 1,86 | NR |
12 | 699 | 700 | + 0,14 | NR |
13 | 5414 | 5086 | - 6,06 | NR |
14 | 2816 | 2602 | - 7,60 | NR |
15 | 1268 | 1095 | - 13,64 | NR |
16 | 1851 | 1644 | - 11,18 | NR |
17 | 11189 | 9691 | - 13,39 | NR |
18 | 4964 | 3713 | - 25,20 | R |
19 | 1047 | 1031 | - 1,53 | NR |
20 | 1869 | 1656 | - 11,40 | NR |
21 | 1629 | 1199 | - 26,40 | R |
22 | 1675 | 1234 | - 26,33 | R |
23 | 1879 | 1722 | - 8,36 | NR |
24 | 2155 | 2103 | - 2,41 | NR |
25 | 668 | 576 | - 13,77 | NR |
26 | 4849 | 4262 | - 12,11 | NR |
27 | 3329 | 3266 | - 1,89 | NR |
28 | 4376 | 3396 | - 22,39 | R |
29 | 3559 | 2863 | - 19,56 | NR |
30 | 2716 | 2932 | + 7,95 | NR |
31 | 4605 | 3569 | - 22,50 | R |
32 | 5025 | 4242 | - 15,58 | NR |
33 | 4239 | 4147 | - 2,17 | NR |
34 | 4334 | 4146 | - 4,34 | NR |
35 | 3691 | 4131 | + 11,92 | NR |
36 | 5841 | 4659 | - 20,24 | NR |
37 | 2201 | 2256 | + 2,50 | NR |
38 | 5578 | 4533 | - 18,73 | NR |